| abstract |
REFERRING TO COMPOUNDS DERIVED FROM PYRIDAZINE OF FORMULA (Ia), WHERE X AND Y ARE 1, 2 OR 3; W IS A DIRECT LINK, C (O) NR1, NR1C (O), AMONG OTHERS; V IS C (O), C (O) O, C (S), AMONG OTHERS; R1 IS H, C1-C6 ALKYL, C2-C6 ALKYL, AMONG OTHERS; R2 IS C1-C12 ALKYL, C2-C12 ALKYL, AMONG OTHERS; R3 IS C1-C12 ALKYL, C2-C12 ALKYL, C1-C12 ALCOXY, AMONG OTHERS; R4 AND R5 ARE H, FLUORINE, CHLORINE, METHYL, AMONG OTHERS; R6, R6a, R7, R7a, R8, R8a, R9 AND R9a ARE H, C1-C3 ALKYL, AMONG OTHERS; R10 IS H O C1-C3 ALKYL; R12 IS H OR C1-C6 ALKYL. PREFERRED COMPOUNDS ARE: 4-METHYLPENTANOIC ACID {6- [4- (2-TRIFLUOROMETHYLBENZOYL) -PIPERAZI-1-NIL] PIRIDAZI-3-NIL} AMIDE, 2-BENZYLOXY-N- {6- [4- (2-TRIFLUOROMETHYLBENZO ) PIPERAZI-1-NIL] -PYRIDAZI-3-NIL} ACETAMIDE, ACID 6- {4- (ISOXAZOL-5-CARBONYL) PIPERAZI-1-NIL] PYRIDAZINE-3-CARBOXYL (3-METHYLBUTYL) AMIDE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SAID COMPOUNDS ARE INHIBITORS OF ESTEAORYL-COA DESATURASE (SDC), PARTICULARLY SDC1 AND ARE USEFUL IN THE TREATMENT OF DISEASES RELATED TO HIGH LEVELS OF LIPIDS, CARDIOVASCULAR SYMPTOMS, OBJECTIVE DISEASES, DIABETES |